ArticleMovement disorders : official journal of the Movement Disorder Society2026
Plasma Neurofilament Light Chain as a Biomarker for Motor Progression and Disease Milestones in Multiple System Atrophy: An Updated Prospective Cohort Study.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPlasma neurofilament light chain (NfL) is a promising biomarker in multiple system atrophy (MSA). This study aimed to evaluate the prognostic utility of both baseline and longitudinal plasma NfL for predicting motor progression, disease milestones, and survival.
methodsThis prospective cohort study enrolled 93 patients with clinically established MSA, and participants were monitored annually for 4 years. Baseline plasma NfL concentrations were quantified using ultrasensitive single molecule array (Simoa™) technology. Disease progression and milestones were systematically assessed at each follow-up using the Unified Multiple System Atrophy Rating Scale (UMSARS). Linear mixed-effects models analyzed the association between NfL and UMSARS progression. Cox proportional hazards models and Kaplan-Meier analyses assessed the relationship between NfL levels, disease milestones, and mortality.
resultsHigher baseline plasma NfL predicted faster progression of UMSARS-I (β = 2.285), UMSARS-II (β = 1.811), and UMSARS-IV (β = 0.267). Patients in the high-risk group (baseline plasma NfL higher than 46.3 pg/mL) had an increased risk of attaining critical milestones, including severe dysarthria (hazard ratio [HR] = 3.85), global disability (HR = 4.54), and mortality (2.28). However, longitudinal NfL trajectories did not correlate with disease progression and prognosis; instead there was a decline in mid-to-late disease course.
conclusionsBaseline plasma NfL, rather than NfL dynamics, represents a promising biomarker for monitoring and predicting poor prognosis in early-stage MSA. Plasma NfL is anticipated to be a biomarker for prognostic stratification of early-stage MSA patients in future clinical trials. © 2026 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.